# Gilenya in Amyotrophic Lateral Sclerosis (ALS)

> **NCT01786174** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 30 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Gilenya
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01786174
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-09
- **Final completion:** 2015-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01786174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01786174, "Gilenya in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01786174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*